转移性三阴性乳腺癌的新型药物治疗进展
Advances in the novel treatment of metastatic triple-negative breast cancer
范嘉躜 1黄硕涵 1孟艳春 2杜琼 1刘继勇 1翟青1
作者信息
- 1. 复旦大学附属肿瘤医院药剂科,上海 200032;复旦大学上海医学院肿瘤系,上海 200032
- 2. 复旦大学附属肿瘤医院肿瘤内科,上海 200032
- 折叠
摘要
三阴性乳腺癌(triple-negative breast cancer,TNBC)侵袭性强,易复发和转移.与其他类型的乳腺癌相比,TNBC早期复发风险更高,预后更差.由于缺乏特异的治疗靶点,目前国内对转移性TNBC(metastatic TNBC,mTNBC)的一线治疗推荐仍以蒽环或紫衫醇(paclitaxel)为基础的单药或联合化疗为主.近年来,随着新型治疗药物在mTNBC中的成功应用,国外己批准一些新型药物用于mTNBC的治疗.该文拟对近年来mTNBC分子分型、免疫以及抗体药物偶联物的研究进展作一综述.
Abstract
Triple-negative breast cancer(TNBC)is aggressive,prone to recurrence and metastasis.There is a higher risk of early recurrence and a worse prognosis compared to other types of breast cancer.Due to the lack of specific therapeutic targets,the first-line treatment recommendations for metastatic TNBC(mTNBC)in China are still mainly based on anthracycline or paclitaxel as monotherapy or combination chemotherapy.In recent years,with the successful application of new therapeutic drugs in mTNBC,some new drugs have been approved for the treatment of mTNBC abroad.This article reviewed the recent advances in mTNBC molecular typing,immunity and antibody drug conjugations.
关键词
转移性三阴性乳腺癌/免疫治疗/抗体偶联药物Key words
metastatic triple-negative breast cancer/immunotherapy/antibody-drug conjugate引用本文复制引用
出版年
2024
NETL
NSTL
万方数据